Ginsenoside Rb1 improves insulin resistance and hepatic steatosis through the activation of the STAT3 pathway, promoting glycolytic enzyme GLUT2 and suppressing gluconeogenic enzyme PEPCK [40,41]. Here, SLC2A2 is linked to Insulin resistance.